MG
NVAX icon

Marex Group’s Novavax NVAX Stock Holding History

Marex Group’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$334K Hold
35,494
– – ﹤0.01% 823
2026
Q1 		$289K Hold
35,494
– – ﹤0.01% 789
2025
Q4 		$239K Buy
35,494
+6,829
+24% +$51.5K ﹤0.01% 789
2025
Q3 		$249K Sell
28,665
-18,317
-39% -$143K ﹤0.01% 665
2025
Q2 		$296K Sell
46,982
-1,315
-3% -$8.71K ﹤0.01% 456
2025
Q1 		$310K Buy
48,297
+23,380
+94% +$193K 0.01% 450
2024
Q4 		$200K Sell
24,917
-4,563
-15% -$44K ﹤0.01% 554
2024
Q3 		$372K Sell
29,480
-4,249
-13% -$54.9K 0.01% 350
2024
Q2 		$427K Buy
33,729
+6,431
+24% +$64.7K 0.01% 332
2024
Q1 		$130K Buy
27,298
+6,196
+29% +$28.7K ﹤0.01% 414
2023
Q4 		$101K Buy
21,102
+7,480
+55% +$45.8K ﹤0.01% 497
2023
Q3 		$98.6K Sell
13,622
-1,483
-10% -$11.8K 0.01% 203
2023
Q2 		$112K Hold
15,105
– – 0.02% 213
2023
Q1 		$105K Buy
15,105
+1,706
+13% +$15.7K 0.01% 244
2022
Q4 		$138K Buy
+13,399
New +$236K 0.02% 242

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Marex Group's NVAX Position: Q2 2026 in Review

Marex Group held its Novavax (NVAX) position steady in Q2 2026 at 35,494 shares worth $334K. The position accounts for ﹤0.01% of the portfolio, ranked #823.

Marex Group first reported a position in NVAX in Q4 2022 and has held it in 15 quarters since. The position peaked at $427K in Q2 2024. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Marex Group held 35,494 shares of Novavax worth $334K as of Q2 2026.
  • Marex Group left its Novavax share count unchanged in Q2 2026.
  • Novavax made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #823 holding.
  • Marex Group first reported a position in Novavax in Q4 2022 and has held it in 15 quarters since.
  • Marex Group's Novavax position peaked at $427K in Q2 2024.
  • 268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.